Recent Press Releases

Management Insights and Media Coverage

Cardax’s Proprietary Astaxanthin Prodrug (CDX-085) Accumulates in Liver, Reduces Elevated Liver Enzymes, and Attenuates Pathohistological Alterations in a Model of Alcohol-Induced Hepatic Stress

By | Science | No Comments
In collaboration with Dr. Steven Weinman, M.D., Ph.D. (Director of the Liver Center at University of Kansas, Kansas City, Kansas), Cardax evaluated the capacity for a proprietary astaxanthin (ASTX) prodrug (CDX-085) to ameliorate oxidative stress-induced hepatic dysfunction in an animal model of disease. In unstressed mice, an 11-day oral administration of 500mg/kg of CDX-085 to mice delivered high levels of ASTX to plasma and liver and importantly liver mitochondria. Eight weeks of CDX-085 treatment (500mg/kg in chow) significantly reduced systemic oxidative stress in vivo measured as diminished MDA levels (TBAR assay, p=0.005).  To further evaluate ASTX influence on disease states,...
Read More

Astaxanthin (ASTX): a natural, safe, powerful and multi-faceted anti-inflammatory with potential in the treatment of Type 2 Diabetes Mellitus (T2DM) and Insulin Resistance (IR)

By | Science | No Comments
By Timothy J. King, Ph.D., Vice President, Research, and A. David Hieber, Ph.D., Associate Director, Biology Type 2 Diabetes Mellitus (T2DM) T2DM is one of the most common age related diseases both in the U.S. and internationally. In 2012, approximately 29.1 million people in the U.S. were currently diagnosed with Type 2 Diabetes Mellitus (T2DM) in addition to as many as 8.1 million (28%) estimated remaining undiagnosed [1]. In addition, approximately 86 million are pre-diabetic in the U.S. T2DM is the 7th leading cause of death and is also the leading cause of kidney failure in the U.S. As of...
Read More

Company Contact

Cardax, Inc.
2800 Woodlawn Drive, #129
Honolulu, Hawaii 96822
Phone: (808) 457-1400
press@cardaxpharma.com